A study found that patients with high circulating endothelial cell counts before treatment were more likely to have growing tumors, while those with low counts remained stable. This test may predict patient outcomes and survival, allowing doctors to tailor treatment and spare unnecessary side effects.
Spasmodic dysphonia is a neurological condition that disrupts nervous signals to the vocal cords. The surgery provided long-lasting resolution of symptoms and improved physical, social, and emotional well-being in most patients, offering a permanent solution for treating the disorder.
Researchers discovered a positive role for gene recruitment to the nuclear periphery, with significant implications for cell polarity and development. The study's findings suggest a complex interplay between nuclear organization and transcriptional regulation.
A new kidney cancer drug has shown a partial response rate of 40% in patients with metastatic renal cell carcinoma, significantly higher than the standard treatment's 15% response rate. The medication, SU11248, was well-tolerated and had significant side effects, but offered improved survival rates for some patients.
A phase II trial found that Herceptin can be used safely for bladder cancer with few serious adverse effects related to the drug. The study showed good responses to treatment in patients with HER2-positive bladder cancer, laying the foundation for a future phase III trial.
Researchers found that adding docetaxel to a combination chemotherapy regimen increased complete pathological response rates by 89% for patients with locally advanced squamous cell carcinoma of the head and neck. The treatment is expected to result in high survival rates, including 95% two-year and 90% five-year survival rates.
A recent study at Fox Chase Cancer Center found that doctors and patients have differing perceptions of clinical trial participation. While both groups agree that clinical trials are crucial for improving cancer treatment, patients are more likely to cite fear of side effects as a barrier to participation.
The Vax1/2 double knock-out mice study reveals the necessary role of Vax genes in blocking the default differentiation pathway for front end brain development. The repression of Pax6 expression is a key step in ventralization of the eye field and subsequent optic nerve development.
Researchers at Mayo Clinic have developed a pharmacogenetic test to determine the best dose of three-drug chemotherapy treatment for various cancers. By analyzing a patient's genetic makeup, they can identify individuals with a higher risk of toxicity from irinotecan and tailor their treatment plan accordingly.